scholarly journals The relationship between Coronary Heart Disease (CHD) and Major Depressive Disorder (MDD): Key mechanisms and the role of quality of life

2013 ◽  
Author(s):  
Adrienne O'Neil
Keyword(s):  
Quality Of Life ◽  
Coronary Heart Disease ◽  
Major Depressive Disorder ◽  
Heart Disease ◽  
Depressive Disorder ◽  
Major Depressive ◽  
The Relationship

The role of dopaminergic agents in improving quality of life in major depressive disorder

2009 ◽  
Vol 11 (6) ◽  
pp. 503-508 ◽  
Author(s):  
Waguih William IsHak ◽  
Michael Davis ◽  
Jessica Jeffrey ◽  
Konstantin Balayan ◽  
Robert N. Pechnick ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Dopaminergic Agents

Major depressive disorder in Latin America: The relationship between depression severity, painful somatic symptoms, and quality of life

2005 ◽  
Vol 86 (1) ◽  
pp. 93-98 ◽  
Author(s):  
Rodrigo A. Muñoz ◽  
Margaret E. McBride ◽  
Alan J.M Brnabic ◽  
Carlos J. López ◽  
Luiz Alberto B. Hetem ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Latin America ◽  
Depressive Disorder ◽  
Somatic Symptoms ◽  
Depression Severity ◽  
Major Depressive ◽  
The Relationship

Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report

2021 ◽  
Author(s):  
Emma Morton ◽  
Venkat Bhat ◽  
Peter Giacobbe ◽  
Wendy Lou ◽  
Erin E. Michalak ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Repeated Measures ◽  
Short Form ◽  
Treatment Phase ◽  
Major Depressive ◽  
Symptomatic Remission ◽  
Substantial Degree

Abstract Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described. Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders (<50% decrease in clinician-rated depression) were treated with adjunctive aripiprazole for 8 weeks (n=97); responders continued escitalopram (n=82). A repeated-measures ANOVA evaluated change in Quality of Life Enjoyment and Satisfaction Short Form scores. QoL was described relative to normative benchmarks. Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL. Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required.

scholarly journals C-QUALITY: Cost and Quality-of-Life Pharmacoeconomic Analysis of Antidepressants in Major Depressive Disorder in Italy

2013 ◽  
Vol 30 (7) ◽  
pp. 697-712 ◽  
Author(s):  
Claudio Mencacci ◽  
Eugenio Aguglia ◽  
Giovanni Biggio ◽  
Lodovico Cappellari ◽  
Guido Di Sciascio ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Pharmacoeconomic Analysis ◽  
Major Depressive ◽  
Quality Cost

Comorbid Social Phobia and Major Depressive Disorder: the Influence of Remission from Depression on Quality of Life and Functioning

2016 ◽  
Vol 12 (3) ◽  
pp. 719-736
Author(s):  
Alexander Joseph Steiner ◽  
Stephanie Marie Wright ◽  
Taylor Kuhn ◽  
Waguih William IsHak
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Social Phobia ◽  
Major Depressive
Sign in / Sign up

Export Citation Format

Share Document